Revenue
2022
2023
2024
2025
Camp4 Therapeutics Corp (CAMP)
Price$4.41Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $3.5M | $652,000 | $350,000 | $0 |
| Research & development | $38.2M | $38.8M | $40.6M | $34.8M |
| Operating expenses | $56.1M | $53.7M | $52.2M | $45.0M |
| Operating income | −$52.6M | −$53.1M | −$51.9M | −$45.0M |
| Operating margin | −1,502.43% | −8,142.33% | −14,822.57% | — |
| EBITDA | −$50.9M | −$51.4M | −$50.2M | −$44.1M |
| EBITDA margin | −1,455.57% | −7,882.21% | −14,343.14% | — |
| Net income | −$80.4M | −$51.8M | −$49.3M | −$44.2M |
| Net profit margin | −2,298.54% | −7,943.40% | −14,083.14% | — |
| Basic EPSper basic share | -$2.65 | -$11.04 | -$124.80 | -$3.64 |
| Diluted EPSper diluted share | -$2.65 | -$11.04 | -$124.80 | -$3.64 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 11, 2025Form 4 | 5AM Ventures VII, L.P. +6TenPercentOwner | BuyCommon Stock · indirect | 2.94M | $1.53 | $4.50M | 2.94M |
| Sep 11, 2025Form 4 | Gold KellyChief Financial Officer | BuyCommon Stock | 6.1K | $1.65 | $10.0K | 67.9K |
| Sep 11, 2025Form 4 | Mandel-Brehm JoshChief Executive Officer | BuyCommon Stock | 6.1K | $1.65 | $10.0K | 278.4K |
| Sep 11, 2025Form 4 | Maricich YuriChief Medical Officer | BuyCommon Stock | 6.1K | $1.65 | $10.0K | 6.1K |
| Sep 11, 2025Form 4 | Young Richard ADirector | BuyCommon Stock | 15.2K | $1.65 | $25.0K | 170.0K |
Community posts
CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, wh ...